502
0 Kommentare
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc. - Seite 3
About Essential Tremor
About 6 million individuals in the U.S. are affected by essential tremor (ET). ET, the most common movement disorder, is characterized by a tremor – an
involuntary shaking or trembling – most often of the hands or arms, which can significantly disrupt daily activities and social interactions.2
About Cavion, Inc.
Cavion, based in Charlottesville, VA and Cambridge, MA, a clinical-stage biotechnology company and
now a wholly-owned subsidiary of Jazz, focuses on therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases. Cavion's portfolio of
T-type calcium channel modulators is being developed to restore the brain's natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson's disease tremor, neuropathic
pain, and epilepsy with absence seizures.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, is dedicated to developing life-changing medicines for people with limited or no options. As a leader in sleep
medicine and with a growing hematology/oncology portfolio, Jazz has a diverse portfolio of products and product candidates in development, and is focused on transforming biopharmaceutical
discoveries into novel medicines. Jazz Pharmaceuticals markets SunosiTM (solriamfetol), Xyrem (sodium oxybate) oral solution, Defitelio (defibrotide sodium), Erwinaze (asparaginase
Erwinia chrysanthemi) and Vyxeos (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Defitelio (defibrotide), Erwinase and Vyxeos 44 mg/100 mg powder for concentrate
for solution for infusion in countries outside the U.S. For country-specific product information, please visit www.jazzpharmaceuticals.com/medicines. For more information, please visit
www.jazzpharmaceuticals.com and follow us on Twitter at @JazzPharma.
Lesen Sie auch
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to the potential benefits to Jazz Pharmaceuticals from the acquisition of Cavion, Inc. and
its lead asset, CX-8998; CX-8998 as a potential treatment for essential tremor; Jazz Pharmaceuticals' plans for future development of CX-8998, including the initiation of a Phase 2 clinical study
in 2020; potential future payments by Jazz Pharmaceuticals to the former Cavion shareholders; and other statements that are not historical facts. These forward-looking statements are based on
Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated
with: Jazz Pharmaceuticals' ability to achieve the expected benefits from the acquisition of Cavion and its lead asset, CX-8998; pharmaceutical product development and the uncertainty of clinical
success, including risks related to failure or delays in initiating or completing clinical trials; the regulatory approval process; and effectively commercializing any product candidates; and other
risks and uncertainties affecting Jazz Pharmaceuticals, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and
Exchange Commission filings and reports (Commission File No. 001-33500), including the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 and
future filings and reports by the company. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect the company's forward-looking statements and may
cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates
indicated in the forward-looking statements, even if they are subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to
update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.